SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00225082 |
Recruitment Status
:
Completed
First Posted
: September 23, 2005
Last Update Posted
: October 5, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4.
Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.
Condition or disease | Intervention/treatment |
---|---|
HIV Infection | Drug: Nucleoside analogue switch |
HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine, and lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be evaluated for clinical lipoatrophy and mitochondrial function prior to switching nucleoside analogues from stavudine (d4T) to tenofovir and after 48 weeks or tenofovir treatment.
Subjects with or without lipoatrophy are eligible for the study. Adipose tissue biopsies to measure mitochondrial function, metabolic laboratory tests, and DAXA scans and clinical evaluations of lipodystrophy will be performed at Entry and after 48 weeks of tenofovir treatment.
Study Type : | Observational |
Actual Enrollment : | 12 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial |
Study Start Date : | November 2004 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | October 2007 |

-
Drug: Nucleoside analogue switch

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- HIV infection
- Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott M97-720 study)
- Planning to switch from stavudine to tenofovir
Exclusion Criteria:
- Will continue to receive stavudine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00225082
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 |
Study Chair: | Robert L Murphy, MD | Northwestern University | |
Study Chair: | Mariana Gerschenson, Ph.D. | University of Hawaii |
Publications of Results:
Responsible Party: | Robert Murphy, MD, Northwestern University |
ClinicalTrials.gov Identifier: | NCT00225082 History of Changes |
Other Study ID Numbers: |
SNAP |
First Posted: | September 23, 2005 Key Record Dates |
Last Update Posted: | October 5, 2010 |
Last Verified: | October 2010 |
Keywords provided by Northwestern University:
Lipoatrophy Mitochondrial function Nucleoside analogue switch Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lipodystrophy Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Skin Diseases, Metabolic Skin Diseases Lipid Metabolism Disorders Metabolic Diseases |